Clinical trials: Hypercytokinemia
Pneumonia, Severe Acute Respiratory Syndrome
Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19
This phase III trial compares low dose whole lung radiation therapy to best supportive care plus physicians choice in treating patients with COVID-19 infection.
- Conditions
- Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- RESCUE1-19 (NCT04433949)
- Testing
- Best Practice, Low Dose Radiation Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
Lymphoma, Lymphoma, B-Cell
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
This research study combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been…
- Conditions
- Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03696784
- Testing
- iC9-CAR19 T cells, Bendamustine, Fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Covid19, Sars-CoV-2 Infection
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing rapidly since the first case found in March 2020 to date.
- Conditions
- Covid19, Sars-CoV-2 Infection, ARDS, Human, Severe covid19
- Trial name
- NCT04715360
- Testing
- autologous activated platelet-rich plasma, Avigan
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- Hayandra Peduli Foundation
Covid19
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Investigators conducted this study to see the effectiveness of Tocilizumab in COVID-19 participants who were in cytokine release syndrome and there was also a control group who received steroids(RECOVERY TRIAL wasn't published or…
- Trial name
- NCT04730323
- Testing
- Tocilizumab
- Where
- Pakistan
- Volunteers
- 93 people
- Sponsor
- FMH College of Medicine and Dentistry
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
COVID-19, Cytokine Storm
Fluoxetine to Reduce Intubation and Death After COVID19 Infection
This project will test the efficacy of fluoxetine to prevent serious consequences of COVID-19 infection, especially death. Becoming sick with COVID-19 virus or any other serious respiratory condition is not fun.
- Trial name
- NCT04377308
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Toledo Health Science Campus
Multiple Myeloma
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig…
- Trial name
- TRI Pro (NCT07589634)
- Testing
- Ramantamig, Tocilizumab
- Where
- 38 sites in United States, Argentina and 7 more
- Volunteers
- 230 people
- Sponsor
- Janssen Research & Development, LLC
Covid19, Cytokine Storm
Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients
SARS-CoV-2 infection induces a hyperinflammatory syndrome, causing the acute respiratory distress syndrome, massive lung cell destruction and, as a plausible sequelae, pulmonary fibrosis in COVID-19 patients.
- Conditions
- Covid19, Cytokine Storm, Regulation of Inflammatory Response, Pulmonary Fibrosis
- Trial name
- NCT04517162
- Testing
- Collagen-Polyvinylpyrrolidone
- Where
- Mexico
- Volunteers
- 90 people
- Sponsor
- Janette Furuzawa Carballeda
Intensive Care Units, ARDS, Human
Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections
Severe Covid-19 (Coronavirus Disease 2019) infections generate major but inappropriate production of cytokines and, in some cases, generate anti-IFN (Interferon) auto-antibodies, inducing acute respiratory distress syndrom…
- Conditions
- Intensive Care Units, ARDS, Human, Covid19
- Trial name
- CovidEP (NCT04751643)
- Testing
- Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3), Usual treatments in intensive care unit according to the current state of knowledge
- Where
- 8 sites in France
- Volunteers
- 21 people
- Sponsor
- Hospices Civils de Lyon
Graft Vs Host Disease, Graft-versus-host-disease
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies.
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
- Trial name
- NCT06008808
- Testing
- Ruxolitinib, Abatacept
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Washington University School of Medicine
Burns, Growth Factors, Combined Defect of
Keratinocyte Growth Factor and Cytokines in Burns.
KERATINOCYTE GROWTH FACTOR AND CYTOKINES IN SKIN BURNS. INTRODUCTION: Intense inflammatory responses are activated by burns that affect a large total body surface area.
- Conditions
- Burns, Growth Factors, Combined Defect of, Inflammation, Cytokine Storm
- Trial name
- NCT01302223
- Where
- Brazil
- Volunteers
- 8 people
- Sponsor
- Federal University of São Paulo
COVID19
Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.
Protection of endothelial dysfunction by intravenous infusion of Defibrotide (Defitelio), expected to decrease inflammation and expression of adhesion molecules in the endothelium, leukocyte tissue infiltration and epithelial…
- Trial name
- DEFACOVID (NCT04348383)
- Testing
- Defibrotide
- Where
- 6 sites in Spain
- Volunteers
- 156 people
- Sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Covid19, Cytokine Storm
UNITE Study (UMN-GE) for COVID-19
The research objective of the UNITE Study is to assess device feasibility of ultrasound application to the spleen to assess its effect on coronavirus disease 2019 (COVID-19) in a pilot study with an off-the-shelf ultrasound GE…
- Conditions
- Covid19, Cytokine Storm, Inflammation
- Trial name
- NCT04701489
- Testing
- Splenic ultrasound
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Relapsed or Refractory Neuroblastoma
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
The purpose of this first in human study is to determine the safety and feasibility of 1RG-CART therapy in patients with relapsed or refractory neuroblastoma.
- Trial name
- NCT02761915
- Testing
- Leukapheresis, Cyclophosphamide, Fludarabine
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Cancer Research UK
Lymphoblastic Leukemia, Acute, Childhood
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated cytokine release syndrome safety events in pediatric patients with CD19 expressing…
- Trial name
- NCT02906371
- Testing
- Tocilizumab, CART 19
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pennsylvania
Acute Respiratory Distress Syndrome, Respiratory Failure
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.
- Conditions
- Acute Respiratory Distress Syndrome, Respiratory Failure, Respiratory Distress Syndrome, Respiratory Tract Diseases
- Trial name
- SUMMIT (NCT06308926)
- Testing
- MRG-001 (Low-dose), MRG-001 (High-dose)
- Volunteers
- 60 people
- Sponsor
- MedRegen LLC
COVID
Colchicine in Patients With Mild and Severe Coronavirus Disease
The world is currently facing a pandemic due to the outbreak of a new coronavirus causing acute respiratory failure called SARS-Cov2.
- Trial name
- ColchiVID (NCT04367168)
- Testing
- Colchicine
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
SARS-CoV 2, SARS
Clinical Trial of Sarilumab in Adults With COVID-19
Early administration of sarilumab in hospitalized patients infected with COVID-19 who have pulmonary infiltrates and are at high risk of unfavorable evolution could decrease/prevent progression to acute respiratory distress…
- Trial name
- SARICOR (NCT04357860)
- Testing
- Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA], Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA], Best available treatment
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Multiple Myeloma
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
- Trial name
- NCT05972135
- Testing
- Teclistamab, Talquetamab, Tocilizumab
- Where
- 17 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
B Cell ALL, B-Cell Lymphoma
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.
- Conditions
- B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma
- Trial name
- NCT04148430
- Testing
- Anakinra
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Memorial Sloan Kettering Cancer Center